Abiopharma

🔍 CLARK IAN T (Director)

Company: Guardant Health, Inc. (GH)

Report Date: 2025-12-05

Detailed Transactions and Holdings:

• Acquired 9,105 shares of Common Stock at $38.42 per share (Direct)
  Date: 2025-12-05 | Code: M | equity_swap_involved: 0 | shares_owned_after: 18,956.00 | transaction_form_type: 4
• Acquired 8,803 shares of Common Stock at $38.005 per share (Direct)
  Date: 2025-12-05 | Code: M | equity_swap_involved: 0 | shares_owned_after: 27,759.00 | transaction_form_type: 4
• Acquired 10,703 shares of Common Stock at $31.84 per share (Direct)
  Date: 2025-12-05 | Code: M | equity_swap_involved: 0 | shares_owned_after: 38,462.00 | transaction_form_type: 4
• Sold 8,156 shares of Common Stock at $106.666 per share (Direct)
  Date: 2025-12-05 | Code: S | equity_swap_involved: 0 | shares_owned_after: 30,306.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 17,055 shares of Common Stock at $107.2703 per share (Direct)
  Date: 2025-12-05 | Code: S | equity_swap_involved: 0 | shares_owned_after: 13,251.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 3,400 shares of Common Stock at $108.0454 per share (Direct)
  Date: 2025-12-05 | Code: S | equity_swap_involved: 0 | shares_owned_after: 9,851.00 | transaction_form_type: 4 | Footnotes: F3
• Sold 9,105 shares of Stock Option (Right to Buy) at $38.42 per share (Derivative)
  Date: 2025-12-05 | Code: M | Expires: 2032-06-15 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F4
• Sold 8,803 shares of Stock Option (Right to Buy) at $38.005 per share (Derivative)
  Date: 2025-12-05 | Code: M | Expires: 2033-06-14 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F5
• Sold 10,703 shares of Stock Option (Right to Buy) at $31.84 per share (Derivative)
  Date: 2025-12-05 | Code: M | Expires: 2034-06-12 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F6

Footnotes:

• F1: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $105.88 to $106.87. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
• F2: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $106.88 to $107.87. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
• F3: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $107.885 to $108.480. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
• F4: The Stock Options vest in full on the one-year anniversary of the grant date, June 15, 2022 or the date of the next year annual stockholders meeting, whichever is earlier.
• F5: The stock option vests in full on the one-year anniversary of the grant date, June 14, 2023 or the date of the next year annual stockholders meeting, whichever is earlier.
• F6: The stock option vests in full on the one-year anniversary of the grant date, June 12, 2024 or the date of the next year annual stockholders meeting, whichever is earlier.